Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Accumulated Expenses (2016 - 2021)

Historic Accumulated Expenses for Assembly Biosciences (ASMB) over the last 7 years, with Q3 2021 value amounting to $3.7 million.

  • Assembly Biosciences' Accumulated Expenses fell 1588.41% to $3.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.7 million, marking a year-over-year decrease of 1588.41%. This contributed to the annual value of $4.4 million for FY2020, which is 1634.04% down from last year.
  • Latest data reveals that Assembly Biosciences reported Accumulated Expenses of $3.7 million as of Q3 2021, which was down 1588.41% from $3.7 million recorded in Q2 2021.
  • In the past 5 years, Assembly Biosciences' Accumulated Expenses ranged from a high of $10.1 million in Q1 2019 and a low of $3.7 million during Q2 2021
  • Over the past 5 years, Assembly Biosciences' median Accumulated Expenses value was $5.0 million (recorded in 2018), while the average stood at $5.6 million.
  • As far as peak fluctuations go, Assembly Biosciences' Accumulated Expenses skyrocketed by 22284.28% in 2017, and later tumbled by 5431.42% in 2020.
  • Over the past 5 years, Assembly Biosciences' Accumulated Expenses (Quarter) stood at $6.1 million in 2017, then fell by 18.37% to $5.0 million in 2018, then increased by 6.01% to $5.3 million in 2019, then decreased by 16.34% to $4.4 million in 2020, then decreased by 15.75% to $3.7 million in 2021.
  • Its Accumulated Expenses stands at $3.7 million for Q3 2021, versus $3.7 million for Q2 2021 and $4.3 million for Q1 2021.